leadf
logo-loader
viewCytoDyn Inc.

CytoDyn's leronlimab delivers health improvements for coronavirus patients in Phase 2 trial

In patients with a Total Clinical Symptom Score of 4 or more, with higher scores indicating a worse health state, leronlimab led to a greater improvement after three days than the placebo

Coronavirus graphic
CytoDyn will report the results to the US Food and Drug Administration (FDA), the UK Medicines & Healthcare products Regulatory Agency (MHRA) and the EU European Medicines Agency

CytoDyn Inc (OTCQB:CYDY) announced Tuesday that its drug leronlimab showed early clinical improvement in mild-to-moderate coronavirus patients in a recently completed Phase 2 trial.

In patients with a Total Clinical Symptom Score of 4 or more, with higher scores indicating a worse health state, leronlimab led to a greater improvement after three days (90% of patient scores improved) than the placebo (71% of scores improved).

"We initiated the study hoping to reduce flu-like symptoms, such as fever, cough, and muscle aches,” Senior Science Advisor Jacob Lalezari said in a statement. “In the end, use of leronlimab was not only correlated with improved symptom scores in patients with measurable symptoms at baseline, but also provided significant and consequential benefits on far more serious endpoints. Demonstrating these efficacy signals in a population with mostly mild illness at study entry bodes well for leronlimab’s activity in patients with more severe illness.”

READ: CytoDyn seeks UK approval for its flagship drug leronlimab for HIV and coronavirus

The study also utilized The National Early Warning Score (NEWS), a scale developed by the Royal College of Physicians to identify patients at risk for rapid clinical deterioration requiring critical care. NEWS2, the latest version, measures clinical parameters including respiratory rate, oxygen saturation, supplemental oxygen, temperature, systolic blood pressure, heart rate, and level of consciousness.

Patients in the leronlimab group were more than twice as likely to experience an improvement in NEWS2 scores than the placebo group after two weeks. Half of leronlimab patients improved by that metric, compared to 20% of placebo patients.

“We are thrilled with the results of leronlimab in mild-to-moderate COVID-19 patients,” Chief Medical Officer Scott Kelly said. “It is paramount to determine which patients will deteriorate and require critical care interventions, including patients at risk for ICU admission, cardiac arrest, or death within 24 hours... We are pleased that leronlimab showed a statistically significant result in a randomized, double-blinded study for NEWS2.”

Safety-wise, the incidence, frequency and severity of adverse events (AEs) and serious adverse events (SAEs) were lower in the leronlimab group than the placebo group. Patients treated with placebo were more than twice as likely to experience SAEs or AEs compared to patients treated with leronlimab, the company said.

“The decreased probability in serious adverse events, as well as overall adverse events with leronlimab compared to placebo further supports the use of leronlimab as a treatment option for COVID-19,” Kelly added.

Going forward, CytoDyn will report the results to the US Food and Drug Administration (FDA), the UK Medicines & Healthcare products Regulatory Agency (MHRA) and the EU European Medicines Agency.

 “In the mild- to-moderate population, it is important to have a therapeutic option for COVID-19 in patients who are showing signs of rapid clinical deterioration,” CEO Nader Pourhassan said. “Patients receiving leronlimab showed a statistically significant improvement using NEWS2 clinical parameters. We will make a case for immediate approval of leronlimab for this population of COVID-19 patients, not only in the US, but in the UK and other countries around the world.”

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: CytoDyn Inc.

Price: 2.6 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.48 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn achieves 75% enrollment for its severe-to-critical coronavirus...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotechnology company has achieved the enrollment of 293 patients with severe-to-critical coronavirus symptoms, meeting the criteria for a second interim analysis by the Data Safety Monitoring Committee (DSMC). Pourhassan says...

1 week, 1 day ago

3 min read